#26: AVANT's Partner, GlaxoSmithKline, Announces New Data Published in The Lancet Show That Rotarix(R) Provides Sustained and Broad Protection During the First Two Years of Life(1)
Note: Shares of AVAN declined amidst positive release of information on a clinical trial.AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN) today announced that new
data from a large European...
NEEDHAM, Mass.--(BUSINESS WIRE)--AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN) today reported financial results for the fourth quarter and year ended December 31, 2006. AVANT reported a...
NEEDHAM, Mass.--(BUSINESS WIRE)--AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN) will release its fourth quarter and fiscal 2006 financial results before U.S. financial markets open on...
NEEDHAM, Mass.--(BUSINESS WIRE)--AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN) today reported a net loss
of $5.6 million, or $.08 per share, for the third quarter of 2006
compared to...
NEEDHAM, Mass.--(BUSINESS WIRE)--AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN) today announced that Dr.
Una S. Ryan, President and Chief Executive Officer of AVANT
Immunotherapeutics,...
NEEDHAM, Mass.--(BUSINESS WIRE)--AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN) will release its third
quarter fiscal 2006 financial results before U.S. financial markets open
on...
NEEDHAM, Mass.--(BUSINESS WIRE)--AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN) announced today the
signing of an extended collaborative research and development agreement
with Pfizer...
#19: AVAN News Fiscal 2007 Defense Appropriations Bill Dedicates $2.6 Million to Ongoing Development of AVANT's Oral Anthrax/Plague Combination Vaccine
NEEDHAM, Mass.--(BUSINESS WIRE)--AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN) today announced that the
Defense Appropriations Bill for Fiscal Year 2007 passed by Congress last
week...
NEEDHAM, Mass.--(BUSINESS WIRE)--AVANT Immunotherapeutics, Inc. (NASDAQ: AVAN) today announced that it
has been awarded a Phase 2 Small Business Innovation Research (SBIR)
grant to...
NEEDHAM, Mass.--(BUSINESS WIRE)--Sept. 20, 2006--AVANT Immunotherapeutics, Inc. (NASDAQ: AVAN) today announced that GlaxoSmithKline (GSK) paid royalties on GSK's sales of Rotarix(R) rotavirus...
NEEDHAM, Mass.--(BUSINESS WIRE)--Aug. 2, 2006--AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN) today reported a net loss of $5.7 million, or $.08 per share, for the second quarter of 2006 compared to...
#15: AVAN News AVANT's CholeraGarde(R) Vaccine Development Program Receives Further Funding from the Gates Foundation; New Support Follows Successful Phase 2 Clinical Trials
NEEDHAM, Mass.--(BUSINESS WIRE)--Aug. 2, 2006--AVANT Immunotherapeutics, Inc. (NASDAQ: AVAN) today announced that the International Vaccine Institute ("IVI") has received $21 million in funding...
NEEDHAM, Mass.--(BUSINESS WIRE)--July 26, 2006-- - Conference Call to Follow - AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN) will release its second quarter fiscal 2006 financial...
#13: AVAN News New Congressional Defense Bill Supports Development and Purchase of Vaccines to Meet the Nation's Public Health Threats; AVANT Expects to Participate in the Development of New Vaccine Technologies to Meet These Threats
NEEDHAM, Mass.--(BUSINESS WIRE)--Dec. 22, 2005--AVANT Immunotherapeutics, Inc. (NASDAQ: AVAN) today announced that the new Congressional defense bill, which passed today and is expected to be...
#12: AVAN News AVANT Immunotherapeutics Announces that Rotarix(R) Rotavirus Vaccine Has Received a Positive Opinion from the European Regulatory Authorities; Partner GlaxoSmithKline Biologicals Seeking to Commercialize Rotarix(R) in Europe in First Half of 200
NEEDHAM, Mass.--(BUSINESS WIRE)--Dec. 15, 2005--AVANT Immunotherapeutics (Nasdaq: AVAN) today announced that its partner GlaxoSmithKline (GSK) Biologicals has received a positive opinion from the...
